Format

Send to

Choose Destination
Curr Opin Oncol. 2003 Jan;15(1):10-5.

Chronic myelogenous leukemia.

Author information

1
Department of Hematology, University College Hospital, Galway, Ireland. michael.odwyer@whb.ie

Abstract

Within the past few years, the introduction of imatinib mesylate (imatinib) has profoundly changed the management of patients with chronic myelogenous leukemia. This review article addresses the recent advances in the treatment of chronic myelogenous leukemia--in particular, maturing data on the use of imatinib in different phases of the disease; the optimal therapy of newly diagnosed patients; the emergence of resistance to imatinib and potential strategies to overcome this problem; and finally, the place of stem cell transplantation in current treatment algorithms.

PMID:
12490756
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center